Curtiss-Wright (CW) Q3 2026 Earnings Call Transcript

Curtiss-Wright reported Q3 2026 sales of $953 million, up 10%, adjusted diluted EPS of $3.94, up 16%, and a record $4.6 billion backlog, up 12% year to date. It raised full-year sales growth guidance to 8%–10% from 8%–9%, with adjusted operating margin of 19.2%–19.4%, EPS of $15.40–$15.60 in the headline takeaways, and free cash flow of $595 million–$615 million; the transcript later gives EPS guidance as $15.40–$15.50. Management cited strong defense and commercial nuclear demand, while noting second-half R&D spending and rising memory prices as margin and cost pressures. The company also plans $460 million in share repurchases and announced facility expansions of $30 million in Texas and $80 million in Pennsylvania; Kevin Rayment is scheduled to become CEO on Jan. 1, 2027.

Analysis

The more durable signal is capacity-constrained, multi-year demand across defense and nuclear—not one quarter’s growth. For CW, backlog can support production visibility, but conversion depends on supplier availability, labor/capacity execution, and customer funding schedules. Memory-cost pressure is a second-order margin risk for Defense Electronics: advance buys and dual sourcing may protect near-term delivery while tying up cash or shifting cost exposure into later periods. Watch segment margins, not just consolidated growth.

Nuclear optionality is being treated as if it were near-term earnings visibility. The stated per-plant content figures are potential lifetime revenue, not booked or annual sales. The AP1000 pump order remains a near-term catalyst, but an order slipping past year-end would weaken the 2027 ramp narrative; deployment schedules and customer financing remain longer-dated risks. Capacity spending raises the cost of being wrong if reactor awards or defense production schedules slip.

The CEO transition appears planned, but the interim CFO role and upcoming strategic reset add execution and disclosure risk into 2027. Immediate reaction may favor CW’s raised outlook and buybacks; over 1–3 months, the AP1000 decision, Q4 Defense Electronics delivery, and memory costs matter more. Over 6–18 months, facility utilization and whether nuclear awards convert to funded work are the key tests. The contrarian point: a record backlog can mask timing and mix risk, while strong cash generation and repurchases may support EPS even if organic growth moderates. Without valuation and post-result price data, the fundamentals support a watch/conditional long, not an unconditional chase.

Key Decisions for Investors

• CW: Favor a staged long on post-results weakness rather than chasing strength, conditional on the share price not already discounting sustained mid-teens growth. Reassess if book-to-bill falls below 1, backlog growth stalls, or full-year guidance is cut.
• Treat the AP1000 pump order as a catalyst, not as confirmed revenue: verify a formal award, scope, and delivery schedule. If no order is announced by year-end, reduce exposure to the near-term nuclear-ramp thesis and revisit 2027 estimates.
• Monitor Defense Electronics margin and cash conversion alongside revenue. Persistent memory-cost pressure, weaker conversion, or a Q4 delivery shortfall would challenge the view that current margin softness is temporary.
• Do not value the Rolls-Royce SMR or AP1000 per-plant content estimates as contracted annual sales; track funded awards, production timing, and facility utilization before underwriting the longer-term nuclear upside.